You are here

Technology in Cancer Research & Treatment

Technology in Cancer Research & Treatment


eISSN: 15330338 | ISSN: 15330346 | Current volume: 22 | Current issue: 1 Frequency: Yearly

Journal Highlights

  • Impact Factor: 2.8
  • Indexed In: Clarivate Analytics: Social Science Index Expanded (Web of Science), PubMed Central, Medline, SCOPUS, EMBASE, Index Medicus, and the DOAJ
  • Fast and double-anonymized peer review by dedicated Associate Editors and Editorial Board Members
  • Global visibility due to international audience of multidisciplinary researchers
  • Publication is subject to payment of an article processing charge (APC)
  • Submit here


Technology in Cancer Research and Treatment (TCRT)
is an open access, peer-reviewed journal which focuses on developments in the detection, diagnosis, prognosis, or treatment of cancer. Please see the Aims and Scope tab for further information.

This journal is a member of the Committee on Publication Ethics (COPE).


Submission Information

Submit your manuscript at https://mc.manuscriptcentral.com/tcrt.

Please see the Submission Guidelines tab for more information on how to submit your article to the journal.


Open access article processing charge (APC) information

Publication in the journal is subject to payment of an article processing charge (APC). The APC serves to support the journal and ensures that articles are freely accessible online in perpetuity under a Creative Commons license.

The article processing charge (APC) for this journal is currently 2650 USD (+VAT where applicable). Original Article (Technical Edit)- 3500; Research Article (Technical Edit)- 3600; Brief Report- 20% discount; Research Note- 20% discount; Technical Note 20% discount; Mini Review- 30% discount; Commentary- 30% discount.

The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here. In some cases, manuscripts may be eligible for a discount or waiver. Please see further details here.

Contact

Please direct any peer review-related queries to tct@sagepub.com. All other queries can be sent to TCRTeditor@sagepub.com.


Why Publish Open Access with TCRT

  • Visibility and Impact: Anyone anywhere in the world can read, use and cite your research
  • Rigorous Standards: Double-anonymized peer review policy
  • Speed: Less than 2 months from submission to first decision and 4 weeks from acceptance to online publication
  • Flexibility: No page limits or page charges, and authors can publish full data sets, figures, tables, etc
  • Copyright: Authors retain copyright under a Creative Commons License

Useful Links

Other information

This journal changed its publication mode from subscription to open access in 2016.

Technology in Cancer Research and Treatment (TCRT) is a gold open access journal indexed in SCIE (Web of Science), PMC, and PubMed: MEDLINE, among other indexing databases. The journal aim is to provide researchers and clinicians with a platform to share and discuss developments in the detection, diagnosis, prognosis, and treatment of cancer.

Article Types and Topics of Interest
TCRT welcomes original research, brief reports, reviews, mini-reviews, study protocols, and commentaries. We encourage submissions relating to advances in the following areas:

Diagnostic or Prognostic 
  • Biomarkers (genes, genetic abnormalities, RNA, proteins, hormones, enzymes)
  • Methods of biomarker detection
  • Cancer biology (cell and molecular biology, immune response, tumor biology, tumor microenvironment)
  • Genetic (DNA damage and repair, epigenetics, gene regulation)
  • Proteomics, Genomics, Systems Biology
  • Epidemiology
  • Imaging technologies (CT scan, MRI, X-ray, Ultrasound)
  • Nuclear medicine scan (Bone, PET, Thyroid, MUGA, Gallium)
  • Biopsy (endoscopic, needle)
  • Emerging technologies
  • Novel applications of existing technologies

 

Treatment

  • Stem cell transplantation
  • Precision/Personalized medicine, Targeted therapy (antibodies, small-molecule drugs)
  • Immunotherapy (adoptive cell transfer, BCG, cytokines, gene therapy, gene transfer, monoclonal antibodies, oncolytic virotherapy, vaccines)
  • Surgery (open or minimally-invasive)
  • Chemotherapy
  • Hormone therapy
  • Radiation therapy (external beam or internal), Brachytherapy
  • Cryosurgery/Cryotherapy
  • Laser therapy (laser-induced interstitial thermotherapy (LITT), interstitial laser photocoagulation)
  • Hyperthermia therapy/Thermal therapy/Thermotherapy
  • Photodynamic therapy (PDT)
  • Irreversible electroporation (IRE)
  • Emerging technologies or novel applications of existing ones

Click here to see a selection of the latest papers published in TCRT

Manuscript Submission

Executive Editor
Jennifer K. Lovick, PhD SAGE Publishing, Thousand Oaks, CA USA
Founding Editor
Mukti H. Sarma, PhD University at Albany - SUNY, New York, USA
Deputy Editor
Applonia Rose, PhD SAGE Publishing, Thousand Oaks, CA USA
Managing Editor
Priyanka Katyal, PhD SAGE Publications, New Delhi, India
Garima Sharma, PhD SAGE Publications, New Delhi, India
Pooja Sharma, MTech SAGE Publications, Dehradun, India
Associate Managing Editor
Simrun Kaur Rathore, MSc SAGE Publications, London, UK
Associate Editors - Cancer Biology
Shiekh Tanveer Ahmad, MS, PhD St. Jude Children’s Research Hospital, USA
Natarajan Aravindan, PhD University of Oklahoma Health Sciences Center, USA
Arya Ashok, PhD Tempus Labs Inc, Chicago, USA
Jiaolin Bao, PhD Hainan University, China
Marc Basson, MD, PhD Northeast Ohio Medical University, Ohio, USA
Rosario Caltabiano, MD University of Catania, Italy
Maja Cemazar, PhD Institute of Oncology, Ljubljana, Slovenia
Parthasarathy Chandrakesan, PhD University of Oklahoma Health Sciences Center, USA
Yu-Chan Chang, PhD National Yang Ming Chiao Tung University, Taiwan
Shengxi Chen, PhD Arizona State University, USA
Shing Cheng Tan Universiti Kebangsaan Malaysia, Malaysia
Xingliang Dai, PhD First Affiliated Hospital of Anhui Medical University, China
Semra Demokan, PhD Istanbul University, Turkey
A. Emre Eskazan, MD Istanbul University-Cerrahpasa, Istanbul, Turkey
Robert Griffin, PhD University of Arkansas, Little Rock, USA
Rohit Gundamaraju, PhD University of Tasmania, Australia
Gamze Guney Eskiler, PhD Sakarya University, Turkey
Lukas J. A. C. Hawinkels, PhD Leiden University Medical Center, The Netherlands
Daniel Wai-Hung Ho, PhD University of Hong Kong, China
Md. Farhadul Islam, PhD Dept. of Biochemistry and Molecular Biology, University of Rajshahi, Bangladesh
Md. Wasim Khan, PhD University of Illinois at Chicago, USA
Dawit Kidane-Mulat, PhD Howard University, College of Medicine, USA
Nameer Kirma, PhD University of Texas Health San Antonio, USA
Sandeep Kumar, PhD The University of Illinois at Chicago, USA
Mafalda Laranjo, PhD University of Coimbra, Portugal
Yun-Han Lee, PhD Keimyung University, South Korea
Huanliang Liu, MD, PhD The Sixth Affiliated Hospital Sun Yat-sen University, China
Wei Liu, PhD, FAAPM, DABR Mayo Clinic Arizona, USA
Jinhui Liu, PhD The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Qian Long, PhD The Second Xiangya Hospital, Central South University, China
Weiren Luo, MD, PhD Southern University of Science and Technology, China
Wenjun Mao, MD, PhD The Affiliated Wuxi People's Hospital of Nanjing Medical University, China
Zukile Mbita, PhD University of Limpopo, South Africa
Jayakumar Nair, PhD National Cancer Institute, USA
Dulal Panda, PhD National Institute of Pharmaceutical Education and Research, Mohali, India
Manoj Pandey, PhD Cooper Medical School of Rowan University, New Jersey, USA
Manash K. Paul, PhD University of California-Los Angeles, USA
Chandra Prakash Prasad, PhD All India Institute of Medical Sciences, New Delhi, India
Liang Qiao, MD, PhD The University of Sydney, Westmead, Australia
Girdhari Rijal, PhD Tarleton State University, a Member of Texas A & M University System, USA
Alessandro Rizzo, MD IRCCS Istituto Tumori Giovanni Paolo II, Italy
Santosh Kumar Singh, PhD Morehouse School of Medicine, Atlanta, USA
Vasudha Srivastava, PhD University of California, San Franciso, USA
Suyan Tian, PhD The First Hospital of Jilin University, China
Yiqing Tian, MM, MD Xinyi People's Hospital, China
Marco A. Velasco-Velazquez, PhD National Autonomous University of Mexico, Mexico
Dong Wang, PhD Chengdu University of Traditional Chinese Medicine, China
Nathaniel Weygant, PhD Fujian University of Traditional Chinese Medicine, China
Qian Xiao, PhD Yale School of Medicine, USA
Zhijie Xu, MD, PhD Xiangya Hospital, Central South University, China
Yanfeng Zhang, PhD University Of Texas Southwest Medical Center, USA
Associate Editors - Detection
Martina Catalano, PhD University of Florence, Italy
Giuseppe De Palma, PhD IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy
Zhong Feng Gao Qilu University of Technology (Shandong Academy of Sciences), China
Francesco Giurazza, MD, PhD, EBIR Cardarelli Hospital of Naples, Italy
Mohamed M. Omran, PhD Helwan University, Egypt
Paolo Spinnato, MD IRCCS Istituto Ortopedico Rizzoli, Italy
Iyad Sultan, MD King Hussein Cancer Center, Amman, Jordan
Arpit Tandon, MS Sciome LLC, USA
Masayuki Tsuneki, DMD, PhD Medmain Research, Medmain Inc., Japan
Rose Wang, PhD University of Missouri at Kansas City, USA
Zhanhong Wu, PhD University of North Carolina at Chapel Hill, USA
Yuhan Yang, MD West China Hospital, Sichuan University, China
Dandan Zheng, PhD University of Nebraska Medical Center, USA
Associate Editors - Diagnosis and Prognosis
Orouba Almilaji, PhD London School of Hygeine and Tropical Medicine, UK
Wei Cao, MD, PhD, DDS National Clinical Research Center for Oral Disease, China
William Cho, PhD Queen Elizabeth Hospital, China
Maria Rosaria De Miglio, MD, PhD University of Sassari, Italy
Jimmy Efird, PhD VA - Cooperative Studies Program Coordinating Center, Boston, MA, USA, & Case Western Reserve University School School of Medicine, Cleveland, OH, USA
Meysam Moghbeli, PhD Masshad University Of Medical Sciences, Iran
Genggeng Qin, MD, PhD Nanfang Hospital, Southern Medical University, China
Ioannis Tsougos, MSc, PhD University of Thessaly, Greece
Liang Wang, MD, PhD China Medical University, China
Yu-Dong Xiao, MD, PhD Second Xiangya Hospital, Central South University, China
Hou-Qun Ying, PhD The Second Affiliated Hospital of Nanchang University, China
Yu-Dong Zhang, PhD University of Leicester, UK
Associate Editors - Treatment
Murat Akant KU Leuven, Belgium
Mumtaz Anwar, PhD University of Illinois at Chicago, USA
Hany Ariffin, PhD Universiti Malaya , Kuala Lumpur, Malaysia
Truls Erik Bjerklund Johansen, PhD Oslo University Hospital, Norway
Chinmoy K. Bose, MD, PhD Netaji Subhas Chandra Bose Cancer Hospital, Kolkata, India
Davide Campobasso, MD University Hospital of Parma, Italy
Hongwei Cheng Xiamen University, Xiamen, Fujian, China
Chih-Yen Chien, MD, FACS Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, Taiwan
James Chow, PhD Princess Margaret Cancer Centre, University of Toronto, Canada
Fabio Cofano, MD University of Torino, Italy
Mengyuan Dai, MD, PhD Wuhan University, China
Satiro De Oliveira, MD David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Bo Deng, MD, PhD Daping Hospital, Army Medical University, China
Ayman El-Baz, PhD University of Louisville, Kentucky, USA
Federico Ferrari University of Brescia, Italy
Matthew Ferris, MD University of Maryland School of Medicine, Baltimore, USA
Gianluca Franceschini Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
Cheng-Maw Ho, MD, PhD National Taiwan University Hospital and College of Medicine, Taiwan
Shigao Huang, PhD Xijing Hospital, Air Force Medical University, China
Xiaotao Jiang, PhD Southern Medical University, China
Xiance Jin, PhD The First Affiliated Hospital of Wenzhou Medical University, China
Juan Jose Segura-Sampedro, PhD University Hospital Son Espases, Spain
Fayçal Kharfi, DSc Ferhat Abbas Setif1 University, Algeria
Fatih Kose Baskent University, Turkey
Savvas Lampridis, PhD Department of Cardiothoracic Surgery, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK
Kujtim Latifi, PhD Moffitt Cancer Center, Tampa, FL USA
Seok Ho Lee Gachon University Gil Medical Center, South Korea
George Li, PhD Memorial Sloan Kettering Cancer Center, USA
Xiaoyang Li MD, PhD National Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
Yixiang Liao, PhD Rush University Medical Center, USA
Qingyu Lin, PhD Sichuan University, China
Wei Liu, PhD, FAAPM, DABR Mayo Clinic Arizona, USA
Chuanbin Mao, PhD University of Oklahoma, USA
Farshad Moradi Kashkooli, PhD Toronto Metropolitan University, Canada
Fatemeh Movahedi, PhD Australian Institute for Bioengineering and Nanotechnology, Australia
Vladimir Neychev University of Central Florida, USA
Nariman Nezami, MD University of Maryland School of Medicine, USA
Qianqian Ni, PhD Medical School of Nanjing University, China
Xinye Ni, PhD Nanjing Medical University, China
Xiaomin Niu, MD, PhD Shanghai Chest Hospital, Shanghai Jiao Tong University, China
Hamed Nosrati Ghent University, Belgium
Antonio Pontoriero, MD University of Messina, Italy
Wenan Qiang, MD, PhD Northwestern University, USA
Zhilei Shen, PhD, DABR University of Southern California, USA
Antonio Sterpetti, MD Sapienza University of Rome, Italy
Timo L.M. Ten Hagen, PhD Erasmus MC, Netherlands
Georgios Tsoulfas, MD, PhD, FACS Aristotle University School of Medicine, Greece
Marco Tucci, MD, PhD University of Bari, Italy
Pietro Valerio Foti, MD University Hospital Policlinico “G. Rodolico-San Marco", Italy
Dong Wang, PhD Chengdu University of Traditional Chinese Medicine, China
Tin Wui Wong, PhD Universiti Teknologi MARA, Malaysia
Shouping Xu National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Song Xu, MD, PhD Tianjin Medical University General Hospital, China
Yuanliang Yan, PhD Xiangya Hospital, Central South University, China
Guan-Jun Yang Ningbo University, China
Xi Yang, MD, PhD Fudan University Shanghai Cancer Center, China
Yidong Yang, PhD, DABR University of Science and Technology of China, China
Lingdi Yin, MD, PhD The First Affiliated Hospital of Nanjing Medical University, China
Baoshe Zhang, PhD University of Maryland School of Medicine, USA
Xin Zhang, PhD Boston University School of Medicine, Boston, MA, USA
Jian-Guo Zhou, MD Universitätsklinikum Erlangen, Germany
Editorial Board
Abass Alavi, MD Perelman School of Medicine, University of Pennsylvania, USA
Robert Alfano, PhD The City College Of New York, CUNY, USA
Filippo Alongi, MD Sacro Cuore Don Calabria Hospital, Negrar-Verona, Italy
Mario Ammirati, MD, MBA St. Rita Medical Center/Mercy Health, Lima OH, USA
Jianfeng Bao Hangzhou Xixi Hospital, Zhejiang University School Of Medicine, Hangzhou, China
John G. Baust, PhD State University of New York, Binghamton, USA
Stewart Becker, PhD New York University, Langone Medical Center, USA
Dzevad Belkic, PhD Karolinska Institute, Stockholm, Sweden
Karen Belkic, MD, PhD Claremont Graduate University, California, USA
Seetharam Bhat, MCh Global Robotics Institute, Florida, USA
Stergios Boussios MD, PhD, FRCP Medway NHS Foundation Trust, Gillingham, UK
Max K. Bulsara, PhD The University of Notre Dame, Australia
George A. Calin, MD, PhD The University of Texas M.D. Anderson Cancer Center, Houston, USA
Jeffrey J. Chalmers, PhD Ohio State University, Columbus, USA
Yong-zi Chen, PhD Tianjin Medical University Cancer Institute and Hospital, China
Gregory Czarnota, MD, PhD Sunnybrook Research Institute, University of Toronto, Canada
Hadassa Degani, PhD The Weizmann Institute of Science, Israel
Ayman El-Baz, PhD University of Louisville, Kentucky, USA
Adel K. El-Naggar, MD, PhD The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
Ammad A. Farooqi, PhD Institute of Biomedical and Genetic Engineering (IBGE), Pakistan
Antonella Fogliata, PhD IRCCS Istituto Clinico Humanitas, Italy
Andrew A. Gage, MD State University of New York, Buffalo, USA
Roberto Gambari, PhD University of Ferrara, Italy
A.H. Gandjbakhche, PhD National Institutes of Health, Bethesda, Maryland, USA
Uwe Haberkorn, PhD University of Heidelberg, Germany
Garret M. Hampton, PhD Genomics Institute of the Novartis Research Foundation, California, USA
Samir Hanash, MD, PhD The University of Texas MD Anderson Cancer Center, USA
Richard Heller, PhD Old Dominion University, USA
Dwight Heron, MD University of Pittsburgh Cancer Institute, Pennsylvania, USA
David Isaacson, PhD Rensselaer Polytechnic Institute, USA
Samie R. Jaffrey, MD, PhD Cornell University, New York, USA
Kewal K. Jain, MD Pharmabiotech, Switzerland
Wei-Lin Jin, MD The First Hospital of Lanzhou University, China
Tomas Kron, PhD Peter MacCallum Cancer Center, Australia
David Larson, MD, PhD University of California, San Francisco, USA
Jay Loeffler, MD, FACR, FASTRO Massachusetts General Hospital, Boston, USA
Kenneth Lundstrom, PhD PanTherapeutics, Switzerland
Lijun Ma, PhD USC Keck School of Medicine, USA
Paola Maycotte, PhD Centro de Investigación Biomédica de Oriente, Puebla, Mexico
William M. Mendenhall, MD Shands Cancer Center, Florida, USA
Arlan H. Mintz, MD University of Pittsburgh, Pennsylvania, USA
Filippo Molinari, PhD Politecnico di Torino, Italy
Sten Myrehaug, PhD Sunnybrook Health Sciences Centre, University of Toronto, Canada
Subir Nag, MD Kaiser Permanente, Santa Clara, California, USA
Yin Kwee Ng, PhD Nanyang Technological University, Singapore
Dattatreyudu Nori, MD, FACR New York Presbyterian Hospital, USA
Yong Peng, PhD Sichuan University, China
Dilini Pinnaduwage, PhD St. Joseph’s Hospital and Medical Center, USA
Tomasz Piotrowski, PhD, DSc Greater Poland Cancer Center, Poznan, Poland
Dimitri Poddighe, MD, PhD-eq. Nazarbayev University School of Medicine & University Medical Center, Kazakhstan
Veena N. Rao, PhD Morehouse School of Medicine, Atlanta, GA, USA
Thomas Reid, MD National Cancer Institute, Bethesda, Maryland, USA
Berkman Sahiner, PhD University of Michigan, Ann Arbor, USA
Olga Savvidou, MD Athens University Medical School, Greece
Daniel Scherman, PhD INSERM, France
Reinhard Schulte, MD Loma Linda University, California, USA
Eva M. Sevick-Muraca, PhD University of Texas Health Sciences Center, Houston, USA
Giuseppe Simone, MD, PhD “Regina Elena” National Cancer Institute, Rome, Italy
Richard Simpson, PhD La Trobe University, Australia
Keshav Singh, PhD University of Alabama, Birmingham, USA
Hany Soliman, MD, FRCPC Sunnybrook Research Institute, University of Toronto, Canada
Luis Souhami, MD McGill University, Canada
Gunnar Steineck, MD, PhD University of Gothenburg, Gothenburg, Sweden
H. Cuneyt Ulutin, MD, PhD Yeni Yuzyil University, Turkey
Xiaoying Wang, PhD Tianjin University of Traditional Chinese Medicine, Tianjin, China
Yihong Wang, MD, PhD Brown University, USA
James S. Welsh, MS, MD, FARCO Stritch School of Medicine Loyola University- Chicago, USA
Andrew Wroe, PhD, DABR Loma Linda University Medical Center, USA
Cedric Yu, PhD University of Maryland, Baltimore, USA
Wenwei Yu, PhD Chiba University, Japan
Baohong Yuan, PhD University of Texas at Arlington, USA
Ning J. Yue, PhD, FAAPM Rutgers Robert Wood Johnson Medical School, New Jersey, USA
Marco Zaider, PhD Memorial Sloan Kettering Cancer Center, New York, USA
Nikolai Zhelev, PhD, CBiol, EurProBiol The University of Dundee, UK
Abdullah Faruk Zorlu, MD Hacettepe University, Turkey
Editorial Review Board
Pankaj Ahluwalia, PhD Augusta University, USA
Bahauddeen Alrfaei, PhD King Abdullah International Medical Research Center (KAIMRC), Saudi Arabia
Richard Amos, MSc, CSci, FIPEM University College London, UK
Eman A. El-maadawy, PhD Universirty of Sadat City, Egypt
Francisco Arenas-Huertero, PhD Hospital Infantil de México Federico Gómez, Mexico
Saleembhasha Asanigari, PhD National Cancer Institute, NIH, USA
Mohammed A Azab, MD Boise State University, USA
Doaa Attia, MD Cleveland Clinic Foundation, USA
Nevim Aygun, PhD Ege University, Turkey
Deepak Babu, PhD Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, USA
Shuheng Bai, MD First Affiliated Hospital of Xi’an Jiaotong University, China
Ganesh Kumar Barik, PhD National Centre for Cell Science, India
Tariq A. Bhat, PhD Roswell Park Comprehensive Cancer Center, USA
Saikat Bhattacharya, PhD Stowers Institute for Medical Research, USA
Andrea Bianconi, MD University of Turin, Italy
Jan Bienkiewicz, MD, PhD Polish Mother's Memorial Hospital Research Institute, Poland
Amany Belal, PhD Beni-Suef University, Egypt
Nrusingh C. Biswal, PhD, DABR Rutgers University, New Jersey, USA
Larry Bodgi, PhD American University of Beirut Medical Centre, Lebanon
Marek Brzezinski, DSc Centre of Molecular and Macromolecular Studies of the Polish Academy of Sciences, Poland
Carlos Cabalag, MBBS, PhD Austin Health, Melbourne, Australia
Boning Cai, MD Chinese PLA General Hospital, China
Deniz Can Güven, MD Hacettepe University Cancer Institute, Turkey
Calogero Casà, MD Fondazione Policlinico Universitario A. Gemelli IRCCS, Italy
Mustafa Cengiz, MD Hacettepe University, Turkey
Pierre-Olivier Champagne, MD, PhD Laval University, Canada
Kanchan Chauhan, PhD Universidad Nacional Autónoma de México, CNyN-UNAM, Mexico
Daici Chen, PhD Sixth Affiliated Hospital of Sun Yat-sen University, China
Kuo-Hu Chen, MD, PhD Taipei Tzu-Chi General Hospital / Tzu-Chi University, Taiwan
Jia Cheng, PhD Zhongshan Hospital Xiamen University, China
Lydia W. T. Cheung, PhD The University of Hong Kong, China
Hao Chi, MD Southwest Medical University, Luzhou, China
Meer Chisthi, MBBS, MS Government Medical College, Trivandrum, India
Hua-Sheng Chiu, PhD Baylor College of Medicine, USA
Ashish P. Chugh, MBBS, MS, MCh Dr. D. Y. Patil Medical College and Hospital, India
Michael D. Chuong, MD Baptist Health South Florida, Miami Cancer Institute, Florida, USA
Selma Corovic, PhD University of Ljubljana, Slovenia
Matteo Costacurta, MD, PhD Blood Cancer Therapeutics Laboratory, Monash University, Australia
Ana Cravo Sá, PhD Instituto Superior Técnico, Portugal
Adriano Carneiro da Costa, MD, PhD Federal University of Pernambuco, Recife, Brazil
Luis Felipe das Chagas e Silva de Carvalho, PhD Universidade de Taubaté and Centro Universitário Braz Cubas, Brazil
Abhijeet P. Deshmukh, PhD The University of Texas MD Anderson Cancer Centre, USA
Ravindra Deshpande, PhD Wake Forest School of Medicine, USA
John DeSisto, PhD University of Colorado, USA
Gagan Dhawan, PhD University of Delhi, India
Ozlem Dilek, PhD University of the District of Columbia, USA
Marisa Domingues dos Santos, MD, PhD Centro Hospitalar Universitário de Santo António, Porto, Portugal
Erison Santana dos Santos, DDS, MSc University of Campinas, Piracicaba, Brazil
Liqin Du, PhD Texas State University, USA
Fatima El Agy Sidi Mohamed ben abdellah university, Morocco
Suganthapriya Elayapillai, PhD The University of Oklahoma Health Science Center, OK, USA
Hagar Elghaaawy, MD, PhD Ain Shams University, Egypt
Soraya Emamgholizadeh Minaei, PhD Urmia University of Medical Sciences, Iran
Zeenat Farooq, PhD University of Illinois at Chicago, USA
Dechao Feng, PhD West China Hospital, Sichuan University, Chengdu, China
Brigida d. Ferreira, PhD Universidade de Lisboa, Portugal
Bruno Fionda, MD Saint Camillus International University of Health and Medical Sciences, Italy
Leonardo Franz, MD University of Padova, Italy
Changran Geng, PhD Nanjing University of Aeronautics and Astronautics, China
Roberto Giovannoni, PhD University of Pisa, Italy
Shunyou Gong, MD, PhD Northwestern University, USA
Gilar Gorji-Bahri, PhD Shahid Beheshti University of Medical Sciences, Iran
Alessandro Granito, PhD University of Bologna, Italy
Fabiana Gregucci, MD Miulli General Regional Hospital, Italy
Andrea E. Guerini, MD University of Brescia, Italy
Nitish Gulve, PhD Ciscovery Bio Inc., Philadelphia, USA
Gamze Guney Eskiler, PhD Sakarya University, Turkey
Marija Habijan, MS Ghent University, Belgium
Shaghayegh Haghjoo Javanmard, MD, PhD Isfahan University of Medical Sciences, Iran
A. Reza Haghpanah, MD University of Medical Sciences, Shiraz, Iran
Ahmed Hammad, PhD National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt
Nemany Hanafy, PhD Kafrelsheikh University, Egypt
Mahmud Hasan, PhD John Hopkins University of Medicine, USA
Hongchao He, MD, PhD Shanghai Jiaotong University School of Medicine, China
Goot Heah Khor, PhD Universiti Teknologi MARA,  Malaysia
Wen Chien Hsi, PhD University of Florida, USA
Chia-Hsien Hsu, PhD Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Taiwan
Tebo Hua, PhD Ningbo Medical Center Lihuili Hospital, China
Baotian Huang, MSc Cancer Hospital of Shantou University Medical College, Shantou, China
Qian Huang, PhD Cleveland Clinic Lerner Research Institute, USA
Yingbo Huang, PhD University of Minnesota, USA
Zhengwei Huang, PhD Jinan University, China
Luis Exequiel Ibarra, PhD Universidad Nacional de Río Cuarto, Argentina
Asma Irshad, PHD University of the Punjab, Lahore, Pakistan
Yasuhito Iwao, MD, PhD Ohta Nishinouchi Hospital, Japan
Jaime Jacqueline Jayaplan, PhD Universiti Malaya, Malaysia
Ameneh Jafari, PhD Shahid Beheshti University of Medical Sciences, Tehran, Iran
Saket Jain, PhD University of California San Francisco, USA
Luis Felipe Jave-Suarez, PhD Instituto Mexicano Del Seguro Social, Mexico
Sheeba Jenifer Sujit, PhD MD Anderson Cancer Center, USA
Keun-Yeong Jeong, PhD Metimedi pharmaceuticals, South Korea
Aimin Jiang, MD The First Affiliated Hospital of Xi’an Jiaotong University, China
Sudhakar Jinka, PhD Vanderbilt University Medical Center, USA
Behrooz Johari, PhD Zanjan University of Medical Sciences, Iran
Shirisha Jonnalagadda, PhD University of Nebraska Medical Center, NE, USA
Sravan Jonnalagadda, PhD University of Nebraska Medical Center, NE, USA
Edward Jung, MD GenesisCare, USA
Erkan Kahraman, PhD Ege University, Turkey
Ferda Kaleagasioglu, PhD Istinye University, Turkey
Vaishali Kapoor, PhD Washington University in St. Louis School of Medicine, USA
Sibel Karaca, PhD Akdeniz University, Turkey
Atsuto Katano, PhD The University of Tokyo Hospital, Japan
Muhammad Khalis Abdul Karim, PhD Universiti Putra Malaysia, Malaysia
Anil Kumar, PhD City of Hope-Biomedical Research Institute, California, USA
Ashok Kumar, PhD All India Institute of Medical Sciences, India
Chan-Yen Kuo, PhD Taipei Tzuchi Hospital, Taiwan
Guiseppe La Rocca, PhD Policlinico A. Gemelli, Roma, Italy
Dennis Larsson, PhD Sahlgrenska University Hospital, Sweden
Shirley Lewis, MD, DNB, FRCR Kasturba Medical College, India
Bingchen Li, PhD Dana-Farber Cancer Institute/Harvard Medical School, USA
Chia-Yang Li, PhD Kaohsiung Medical University, Taiwan
Mengshi Li, PhD The University of Iowa, USA
Tian Li, PhD The Hong Kong Polytechnic University, Hong Kong, China
Xiaodong Li, PhD The Third Affiliated Hospital of Soochow University, China
Yiran Li, MD, PhD Shanghai Tongji University, China
Liang Liu, MD Baoding No. 1 Central Hospital, Baoding, China
Sanxiong Liu, PhD NYU Langone Health, USA
Kevin Lu, MD Taichung Veterans General Hospital, Taichung City, Taiwan
Wenying Lu, PhD University of Tasmania, Australia
Jun Lyu, MD, PhD The First Affiliated Hospital of Jinan University, China
Zhongliang Ma, PhD Shanghai University, China
Rashmi Madda, PhD Pacific Northwest National Laboratory, Washington, USA
Manish Devendra Mair, MS John Hunter Hospital, Australia
Dipak Maity, PhD University of Petroleum & Energy Studies, Dehradun, India
Paramita Mandal, PhD The University of Burdwan, India
Tessho Maruyama, PhD University of the Ryukyus, Okinawa, Japan
Marwa Matboli, MD Ain Shams Faculty of Medicine, Egypt
J. Michael Mathis, PhD University of North Texas Health Science Center, USA
Abid Mattoo, PhD Ultragenyx Pharmaceuticals, USA
Stephanie May, PhD The Beatson Institute for Cancer Research, Glasgow, UK
Fiona McDonald, PhD University of Otago, New Zealand
Gavin McStay, PhD Liverpool John Moores University, UK
Nileshkumar Meghani, PhD Inimmune Corp, USA
Pallavi Mehta, MD Rajiv Gandhi Cancer Institute and Research Center, India
Jialin Meng, MD, PhD First Affiliated Hospital of Anhui Medical University, China
Bradley Mills, PhD University of Rochester Medical Center, USA
Disha Mittal, PhD Galgotias University, India
Wafaa M Rashed, PhD Children's Cancer Hospital, Egypt
Sujan Kumar Mondal, PhD Michigan State University, East Lansing, USA
Jitender Monga, MPharm, PhD Henry Ford Health System, USA
Amr Muhammed, PhD Sohag University, Egypt
Amar N. Mukerji, MD, MS, FACS Heartland Regional Medical Centre, Marion, IL, USA
Kumuraswamy Naidu Chitrala, PhD Fels cancer institute for Personalized Medicine, USA
Lui Ng, PhD Hong Kong University, Hong Kong, China
Saumya Nigam, PhD Michigan State University, USA
Ashish Noronha, PhD University of California-San Francisco, USA
Joseph Norris, MSc, MRCS, FESSR University College London (UCL), UK
Livesey D. Olerile, PhD DDT College of Medicine, Botswana
Mohamed M. Omran, PhD Helwan University, Egypt
Aytug Onan, PhD Izmir Katip Celebi University, Turkey
Chunlin Ou, PhD Xiangya Hospital, Central South University, China
P. S. Suresh, PhD National Institute of Technology, Calicut, India
Rahul Pal, PhD Massachusetts General Hospital, Boston, USA
Ashok Palaniappan, PhD SASTRA Deemed University, India
Antonio Palumbo Júnior, PhD Federal University of Rio de Janeiro, Brazil
Nikolaos Pararas, MD, PhD Attikon Hospital, National and Kapodistrian University of Athens, Greece
Arthur Paredes Gatti, MD UNIFESP / ICESP, Brazil
Jiyeon Park, PhD University of Florida College of Medicine, USA
Seungjo (Joe) Park, PhD The University of Alabama, USA
Rajiv Pathak, PhD Albert Einstein College of Medicine, USA
Filippo Patrucco University of Eastern Piedmont, Italy
Yamuna Phal, PhD Colorado School of Mines, USA
Maciej Pietrzak, PhD The Ohio State University, USA
Adam Polat, PhD Harvard Medical School, Brigham and Women's Hospital, MA, USA
Naresh Poondla, PhD Icahn School of Medicine at Mount Sinai, New York, USA
Veselin Popov, MD, PhD Medical University Plovdiv, Bulgaria
Guruvaiah Praveen, PhD Columbia University Irving Medical Center, USA
Phillip Prior, PhD Medical College of Wisconsin, USA
Chamindie Punyadeera, PhD Griffith Institute for Drug Discovery, Australia
Ming Qi, PhD Jinan University, China
Wanqiong Qiao, PhD Stanford University, USA
Laleh Rafiee, PhD Isfahan University of Medical Sciences, Iran
Janaki Ramaiah, PhD Koneru Lakshmaiah Education Foundation, India
Leila Rezakhani, Kermanshah University of Medical Sciences, Iran
Hanguang Ruan, MD, PhD Gunma University Hospital, Japan
Subhransu Sahoo, PhD University of Texas Southwestern Medical Center, USA
Abbas Salihi, PhD Salahaddin University, Iraq
Yazdan Salimi, MSc University of Geneva, Geneva, Switzerland
Samson Mathews Samuel, M.Phil, PhD Weill Cornell Medicine, Qatar
Rahul Sanawar, PhD Albert Einstein College of Medicine, USA
Rahul Sankrityayan Kanumuri, PhD Indiana University-Purdue University Indianapolis, USA
Sabrina Sarker, PhD Technical University of Munich, Germany
Mohammed Sayed Mohammed, PhD National Cancer Institute, Cairo University, Egypt
Yasemin Saygideger, MD, PhD Cukurova University, Turkey
Stefano Scabini, MD IRCCS Ospedale Policlinico San Martino - Genoa, Italy
Prakhar Sengar, PhD Centro de nanociencias y nanotecnología, UNAM, Mexico
Vishal Shah, PharmD, MBA Mayo Clinic, Phoenix, Arizona, USA
Lipei Shao, PhD Center for Cellular Engineering, National Institutes of Health, U.S.
Ankit Sharma, PhD LabyRx Immunologic Therapeutics Pvt Ltd, Sacramento, USA
Deepika Sharma, PhD Institite of Nano Science and Technology, India
May Shawki, PhD Ain Shams University, Egypt
Jie Shen, PhD University of Virginia, USA
Qiao Shi, MD, PhD Renmin Hospital of Wuhan University, Wuhan, China
Chun-Chien Shieh, PhD The University of Sydney, Australia
Jian Shu, PhD School of Medicine, Faculty of Life Science & Medicine Northwest University, Xi'an, China
Valentina Siino, PhD Acrivon Therepeutics, USA
Manpreet Singh, PhD University of Maryland, Baltimore, USA
Virendra Singh Jawaharlal Nehru University, India
Sanju Sinha, PhD National Cancer Institute, NIH, Bethesda, USA
Simon John Christoph Soerensen, MD Stanford University, USA
Jafar Soleymani, PhD Tabriz University of Medical Sciences, Iran
Sourabh Soni, PhD Brigham and Women's Hospital, Harvard Medical School, Boston, USA
Govindarajan Srimathveeravalli, PhD Memorial Sloan Kettering Cancer Center, New York, USA
Yilun Sun, PhD National Cancer Institute, NIH, USA
Yunus Kasim Terzi, PhD Baskent University, Ankara, Turkey
Yasin Tuluce, PhD Van Yüzüncü Yil Üniversity, Turkey
Ram Babu Undi, PhD The University of Oklahoma Health Sciences Center, USA
Eduardo López Urrutia, PhD Universidad Nacional Autónoma de México Facultad de Estudios Superiores Iztacala, Mexico
Antti Vanhanen, PhD Tampere University Hospital, Finland
Miguel Ángel Velázquez Flores, DSc Instituto Mexicano Del Seguro Social, Mexico
Ganesh Venkatraman, PhD Sri Ramachandra Institute of Higher Education and Resesarch, India
Domenico Viggiano, MD University Hospital Careggi, Italy
Sekar Vijayakumar, PhD Marine College, Shandong University,Weihai, China
Austin W.T Chiang, PhD University of California-San Diego, USA
Chunhao Wang, PhD Duke University Medical Center, Durham, North Carolina, USA
Huali Wang, PhD The University of Hong Kong-Shenzhen Hospital, China
Li Wang, MD, PhD The Hormel Institute, University of Minnesota, USA
Siwen Wang, MD The First Affiliated Hospital of Sun Yat-sen University, China
Wei Wang, MD, PhD Beijing Chao-Yang Hospital, Capital Medical University (CCMU), China
Ya-Wen Wang, MD Qilu Hospital of Shandong University, China
Yumin Wang, MD Xiangya Hospital, Central South University, China
Ujjwala M.Warawdekar, PhD Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, India
Christopher Wasson, PhD University of Leeds, United Kingdom
Wei Wei, PhD Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, China
Ching-Feng Weng, PhD University of Maryland at Baltimore, USA
Xiaofeng Wu, PhD Pfizer Inc., Connecticut, USA
Jiajia Xi, PhD Lerner Research Institute, Cleveland Clinic, USA
Feng Xu, MD, PhD Shantou University Medical College, China
Yingkun Xu, PhD Chongqing Medical University, China
Abdullah Yalcin, PhD Bursa Uludag University, Bursa, Turkey
Wenhui Yi, PhD Xi’an Jiaotong University, China
Liang Yin, PhD People's Hospital of Jiangsu University, Zhenjiang, China
Yu Chaoran, PhD Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China
Yang Yuan, MD The First Hospital of Lanzhou University, China
Zhongyue (Claire) Yuan, MSc Purdue University, USA
Zeki Yumuk, MD, PhD Kocaeli University, Turkey
Chao Zhang, PhD, MA, MPH General Dynamics Information Technology, Inc., USA
Shuaishuai Zhang, PhD South China Normal University, China
Xiaoying Zhou MD, PhD Guangxi Medical University, China
Yue Zou, PhD Weill Cornell Medical College, USA
  • Clarivate Analytics: Science Citation Index Expanded (SCIE)
  • EMBASE/Excerpta Medica
  • Index Medicus
  • ProQuest
  • PubMed: MEDLINE
  • Scopus
  •  

    Before you submit your research, please make sure your paper meets the below criteria:

    1. Your paper is an original work and has not been published or currently under review with another journal.

    2. Only authors that have contributed to the work are added. Please see ICMJE's guidelines "Defining Roles of Authors and Contributors". 

    3. Your work meets all Research Ethics and Reporting Standards. Many study types require a workflow as a figure and/or a completed checklist uploaded as a supplementary file for peer review. Visit here to see if your study type requires a workflow and/or checklist.

    4. Your figures are of acceptable quality and uploaded as separate files. Line art should be 900-1200 DPI, images 300 DPI. Images should be minimally processed to uphold their original integrity. More figure information here. 

    5. Your references are formatted correctly and numbered as they appear in the text. Please visit here for reference style.  

    6. Data and complete methods should be made available so that others may replicate your study. If applicable, please see here for more information and data repositories.  

    7. Please download and include the following forms when submitting your paper (some papers may require multiple forms).

      1. For life science research papers, please download this Data Presentation Checklist and submit it with your paper.

      2. For clinical papers, please download and attach the following Ethics Declaration Form and submit it along with your paper.

      3. For animal research papers, please download the following ARRIVE Compliance Form and submit it along with your paper. 

    8. Authors must have an understanding and agreement to pay any applicable article processing charges (APCs).

    9. Only manuscripts of sufficient quality that meet the aims & scope of the journal will be reviewed.

    10. Full guidelines are below. Submissions that don't adhere to these instructions will be returned prior to peer review. 

    Once your manuscript meets all criteria above and below, you can submit it through our online submission system here.

    This Journal is a member of the Committee on Publication Ethics.

    This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing,
    and Publication of Scholarly Work in Medical Journals
    formulated by the International Committee of
    Medical Journal Editors (ICMJE).

    Please read the guidelines below then visit the journal’s submission site
    https://mc.manuscriptcentral.com/TCRT to upload your manuscript. Please note that manuscripts not
    conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.

    Please also be sure to look over the submission checklist here before submitting.

    Sage Publishing disseminates high-quality research and engaged scholarship globally, and we are committed to diversity and inclusion in publishing. We encourage submissions from a diverse range of authors from across all countries and backgrounds.

    Only manuscripts of sufficient quality that meet the aims and scope of Technology in Cancer Research &
    Treatment
    will be reviewed.

    As part of the submission process, you will be required to warrant that you are submitting your original
    work, that you have the rights in the work, that you are submitting the work for first publication in the
    Journal and that it is not being considered for publication elsewhere and has not already been published
    elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of
    any copyright works not owned by you.

    Please Read the Manuscript Submission Guidelines below before submitting your manuscript here:
    SUBMIT MANUSCRIPT

     

    1. Open Access
    2. Article processing charge (APC)
    3. What do we publish?
      3.1 Aims & scope
      3.2 Article types
      3.2.1 Original research articles
      3.2.2 Review articles
      3.2.3 Mini Review articles
      3.2.4 Study Protocol articles
      3.2.5 Opinion pieces
      3.2.6 Letters to the Editor
      3.2.7 Editorials
      3.2.8 Validation Studies
      3.3 Writing your paper
      3.3.1 Making your article discoverable 
    4. Editorial policies
      4.1 Peer Review Policy
      4.2 Authorship
      4.3 Acknowledgements
      4.4 Funding
      4.5 Declaration of conflicting interests
      4.6 Research ethics and patient consent
      4.7 Clinical Trials
      4.8 Reporting guidelines
      4.9 Research Data
    5. Publishing policies
      5.1 Publication ethics
      5.1.1 Plagiarism
      5.1.2 Prior publication
      5.2 Contributor's publishing agreement
    6. Preparing your manuscript
      6.1 Word processing formats
      6.1.1 Title and Authors (On a separate title page)
      6.1.2 Manuscript Preparation
      6.2 Artwork, figures and other graphics
      6.3 Supplemental material
      6.4 Reference style
      6.5 English language editing services
    7. Submitting your manuscript
      7.1 How to submit your manuscript
      7.2 Title, keywords and abstracts
      7.3 Information required for completing your submission
      7.4 ORCID
      7.5 Information required for completing your submission
      7.6 Permissions
    8. On acceptance and publication
      8.1 Sage Production
      8.2 Online publication
      8.3 Promoting your article
    9. Further information

    1. Open Access

    Technology in Cancer Research & Treatment is an open access, peer reviewed journal. Each article
    accepted by peer review is made freely available online immediately upon publication, is published
    under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the
    journal are covered by the collection of article processing charges which are paid by the funder,
    institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to
    the journal.

    For general information on open access at Sage please visit the Open Access page or view our Open
    Access FAQs
    .

    Back to top

    2. Article processing charge (APC)

    If, after peer review, your manuscript is accepted for publication, a one-time article processing charge
    (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely
    available online in perpetuity under a Creative Commons license.

    The APC for this journal is $2,650 USD (+VAT where applicable*). Original Article (Technical Edit)- 3500; Research Article (Technical Edit)- 3600; Brief Report- 20% discount; Research Note- 20% discount; Technical Note 20% discount; Mini Review- 30% discount; Commentary- 30% discount.

    Back to top

    3. What do we publish?

    3.1 Aims & scope

    Before submitting your manuscript to Technology in Cancer Research & Treatment, please
    ensure you have read the Aims & Scope.

    For studies that only contain bioinformatics, computational analysis, or predictions made using public databases, the journal only considers those manuscripts which include robust external validation using an independent cohort or biological validation in vitro or in vivo and have potential clinical applications.

    3.2 Article types

    3.2.1 Original research articles

    Original, in-depth, research articles must follow the Aims & Scope of TCRT with emphasis on prevention, diagnosis, treatment, and monitoring of cancer. Research articles must have the potential for clinical application. For bioinformatics studies, external clinical validation is expected. For in vitro studies, a molecular mechanism should be presented. TCRT does not impose word or figure limits, but does reserve the right to ask for manuscripts to be edited and/or shortened.

    3.2.2 Review articles

    Review Articles should report on the existing state of understanding in a specific
    research area and/or topic. TCRT does not impose word or figure limits but does
    reserve the right to ask for manuscripts to be edited and/or shortened.

    3.2.3 Mini Review articles

    Mini Reviews are articles that focus on recent significant advances in fields that are within the scope of TCRT. They are clear, succinct summaries that provide an up-to-date overview of progress, new developments, and/or emerging concepts in a specific field. Mini Reviews must provide clinical context and discussion of challenges and potential future developments. Mini Reviews should be approximately 2000 words. The abstract should not exceed 350 words and should be structure with a background, main body, and short conclusion. Mini Reviews should not include unpublished material or personal communications.

    3.2.4 Study Protocol articles

    Study Protocols are articles that describe the design of planned or ongoing research. This includes study design for observational, qualitative, exploratory studies, experimental studies, and systematic reviews. Study designs for clinical trials are especially encouraged. TCRT endorses the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) Statement, which provides important guidance on drafting protocols, and the PRISMA-P (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, which provide a 17-item checklist for preparing systematic review and meta-analysis protocols. Authors are encourage to follow these guidelines when preparing a study protocol manuscript. For more information on preparing a Study Protocol for submission, refer to this document.

    3.2.5 Opinion pieces

    Opinion Pieces should not exceed four printed pages. Papers in this section should
    present a new vision or perspective of recent developments. They may also critically
    address recent publications from any journal. In the latter case, the criticized authors
    will be given a chance to write a prompt response. Articles in this section should address
    unsolved controversies arising in current research.

    3.2.6 Letters to the Editor

    Letters to the Editor should consist of one or two paragraphs totaling no more than 500 words, no abstract, no subheadings and fewer than 8 references (one author, et al., no titles). If an
    abstract is included, it will automatically be made the first paragraph. Letters should not include
    figures or research material. Letters to the editor are not charged an APC.

    A letter to the editor is a brief communication that addresses the contents of a published article.Its purpose is to make corrections, provide alternative viewpoints, or offer counter-arguments. Avoidlogical fallacies and ad hominem attacks. Letters to the editor must be written in a professional tone and include references to support all claims if appropriate.

    3.2.7 Editorials

    Editorials are short articles intended to provide a brief overview of the latest research in the field. These key opinion pieces are peer reviewed and is aimed at steering discussion about the recent exciting developments in cancer research and therapy. The word limit for editorial articles is maximum 2000 words and up to 20 references.

    3.2.8 Validation Studies

    Validation or Replication studies can be submitted to the journal. These should be carried out to validate that a scientific finding is accurate, reliable and reproducible. These may be written in the style of a Brief Communication or a Research Paper with a brief introduction.

    3.3 Writing your paper

    The Sage Author Gateway has some general advice and on how to get published, plus links to further resources. Sage Author Services also offers authors a variety of ways to improve and enhance their article including English language editing, plagiarism detection, and video abstract and infographic preparation.

    3.3.1 Making your article discoverable 

    When writing up your paper, think about how you can make it discoverable. The title,
    keywords and abstract are key to ensuring readers find your article through search
    engines such as Google. For information and guidance on how best to title your article,
    write your abstract and select your keywords, have a look at this page on the Gateway:
    How to Help Readers Find Your Article Online

    Back to top

    4. Editorial policies

    4.1 Peer review policy

    Technology in Cancer Research & Treatment offers transparent peer review as a choice for authors, where the reviews at each stage, author responses and editor’s decision letters will be publicly available on the ScholarOne Transparent Peer Review platform and linked to from the published article should the article be accepted. Authors have the opportunity to opt-out during submission. Reviewers are encouraged to sign their reviews but their comments will be published anonymously should they choose not to do so.

    The journal’s policy is to have manuscripts reviewed by two expert reviewers. Technology in Cancer Research & Treatment utilizes a double-blind peer review process in which the reviewer and authors’ names and information are withheld from the other. All manuscripts are reviewed as rapidly as possible while maintaining rigor. Reviewers make comments to the author and recommendations to the Managing Editor who then makes the final decision. 

    **When uploading your manuscript, please make sure no identifying information is included
    in the main document, including in the acknowledgments, funding and conflict of interest
    statements. If any of these statements contain identifying information, please put the
    statements on the title page.

    Technology in Cancer Research & Treatment is committed to delivering high quality, fast peer review
    for your paper, and as such has partnered with Publons. Publons is a third party service
    that seeks to track, verify and give credit for peer review. Reviewers for Technology in Cancer
    Research & Treatment
    can opt in to Publons in order to claim their reviews or have them
    automatically verified and added to their reviewer profile. Reviewers claiming credit for their
    review will be associated with the relevant journal, but the article name, reviewer’s decision and
    the content of their review is not published on the site. For more information visit the Publons
    website.

    The Editor or members of the Editorial Board may occasionally submit their own manuscripts for
    possible publication in the journal. In these cases, the peer review process will be managed by
    alternative members of the Board and the submitting Editor/Board member will have no
    involvement in the decision-making process.

    4.2 Authorship

    Papers should only be submitted for consideration once consent is given by all contributing
    authors. Those submitting papers should carefully check that all those whose work contributed
    to the paper are acknowledged as contributing authors.
    The list of authors should include all those who can legitimately claim authorship. This is all
    those who:

    (i) Made a substantial contribution to the concept or design of the work; or acquisition,
    analysis or interpretation of data,
    (ii) Drafted the article or revised it critically for important intellectual content,
    (iii) Approved the version to be published,
    (iv) Each author should have participated sufficiently in the work to take public
    responsibility for appropriate portions of the content.

    Authors should meet the conditions of all of the points above. Each author should have
    participated sufficiently in the work to take public responsibility for appropriate portions of the
    content.

    When a large, multicentre group has conducted the work, the group should identify the
    individuals who accept direct responsibility for the manuscript. These individuals should fully
    meet the criteria for authorship.

    Acquisition of funding, collection of data, or general supervision of the research group alone
    does not constitute authorship, although all contributors who do not meet the criteria for
    authorship should be listed in the Acknowledgments section. Please refer to the International
    Committee of Medical Journal Editors (ICMJE) authorship guidelines
    for more information on
    authorship.

    Please note that AI chatbots, for example ChatGPT, should not be listed as authors. For more information see the policy on Use of ChatGPT and generative AI tools.

    4.3 Acknowledgements

    All contributors who do not meet the criteria for authorship should be listed in an Acknowledgments section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.

    Please supply any personal acknowledgements separately to the main text to facilitate anonymous peer review.

    4.3.1 Third party submissions

    Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:

    • Disclose this type of editorial assistance – including the individual’s name, company and level of input
    • Identify any entities that paid for this assistance
    • Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.

    Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.

    4.3.2 Writing assistance

    Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.
    It is not necessary to disclose use of language polishing services.

    Please supply any personal acknowledgments separately to the main text to facilitate anonymous peer review.

    4.4 Funding

    Technology in Cancer Research & Treatment requires all authors to acknowledge their funding in
    a consistent fashion under a separate heading. Please visit the Funding Acknowledgements
    page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in
    the event of funding, or state: This research received no specific grant from any funding
    agency in the public, commercial, or not-for-profit sectors.

    4.5 Declaration of conflicting interests

    It is the policy of Technology in Cancer Research & Treatment to require a declaration of
    conflicting interests from all authors enabling a statement to be carried within the paginated
    pages of all published articles.

    Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of
    your manuscript, after any acknowledgments and prior to the references. If no conflict exists,
    please state that ‘The Author(s) declare(s) that there is no conflict of interest’.

    For guidance on conflict of interest statements, please see the ICMJE recommendations.

    4.6 Research ethics and patient consent

    Medical research involving human subjects must be conducted according to the World Medical
    Association Declaration of Helsinki
    .

    Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct,
    Reporting, Editing, and Publication of Scholarly Work in Medical Journals
    , and all papers
    reporting animal and/or human studies must state in the methods section that the relevant
    Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure 
    that you have provided the full name and institution of the review committee, in addition to the
    approval number.

    For research articles, authors are also required to state in the methods section whether participants
    rovided informed consent and whether the consent was written or verbal.

    Information on informed consent to report individual cases or case series should be included in the
    manuscript text. A statement is required regarding whether written informed consent for patient information
    and images to be published was provided by the patient(s) or a legally authorized representative. Please
    do not submit the patient’s actual written informed consent with your article, as this in itself breaches the
    patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained
    written informed consent but the written consent itself should be held by the authors/investigators
    themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your
    submission as a separate file.

    Please also refer to the ICMJE Recommendations for the Protection of Research Participants.

    All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.

    4.7 Clinical trials

    Technology in Cancer Research & Treatment conforms to the ICMJE requirement that clinical
    trials are registered in a WHO-approved public trials registry at or before the time of first patient
    enrolment as a condition of consideration for publication. The trial registry name and URL, and
    registration number must be included at the end of the abstract.

    4.8 Reporting guidelines

    The relevant EQUATOR Network reporting guidelines should be followed depending on the type
    of study. For example, all randomized controlled trials submitted for publication should include
    a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should
    be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses
    should include the completed PRISMA flow chart as a cited figure and the completed
    PRISMA checklist should be uploaded with your submission as a supplementary file. Observational studies in epidemiology (cohor, case-control, cross-sectional studies) should include the completed STROBE checklist as a supplementary file with your submission. Animal studies should have the completed ARRIVES checklist uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.

    Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.

    4.9 Research data

    The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages

    Subject to appropriate ethical and legal considerations, authors are encouraged to:

    • share your research data in a relevant public data repository
    • include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
    • cite this data in your research

    Back to top

    5. Publishing policies

    5.1 Publication ethics

    Sage is committed to upholding the integrity of the academic record. We encourage authors to
    refer to the Committee on Publication Ethics’ International Standards for Authors and view the
    Publication Ethics page on the Sage Author Gateway.

    5.1.1 Plagiarism

    Technology in Cancer Research & Treatment and Sage take issues of copyright infringement,
    plagiarism or other breaches of best practice in publication very seriously. We seek to protect
    the rights of our authors and we always investigate claims of plagiarism or misuse of published
    articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted
    articles may be checked with duplication-checking software. Where an article, for example, is
    found to have plagiarized other work or included third-party copyright material without
    permission or with insufficient acknowledgement, or where the authorship of the article is
    contested, we reserve the right to take action including, but not limited to: publishing an
    erratum or corrigendum (correction); retracting the article; taking up the matter with the head
    of department or dean of the author's institution and/or relevant academic bodies or societies;
    or taking appropriate legal action.

    5.1.2 Prior publication

    If any material has been previously published, it is not generally acceptable for publication in a Sage
    journal. However, there are certain circumstances where previously published material can be
    considered for publication. Please refer to the guidance on the Sage Author Gateway or if in
    doubt, contact the Editor at the address given below.

    5.2 Contributor's publishing agreement

    Before publication Sage requires the author as the rights holder to sign a Journal Contributor’s
    Publishing Agreement. Technology in Cancer Research & Treatment publishes manuscripts
    under Creative Commons licenses. The standard license for the journal is Creative Commons by
    Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without
    permission as long as the work is properly referenced and the use is non-commercial. For more
    information, you are advised to visit Sage's OA licenses page.

    Alternative license arrangements are available, for example, to meet particular funder
    mandates, made at the author’s request. 

    Back to top

    6. Preparing your manuscript

    6.1 Word processing formats

    Preferred formats for the text and tables of your manuscript are Word DOC, RTF, XLS. LaTeX files
    are also accepted. The text should be double-spaced throughout and with a minimum of 3cm for
    left and right hand margins and 5cm at head and foot. Text should be standard 10 or 12 point.
    TCRT follows IUPAC-IUB nomenclature. Word and (La)Tex templates are available on the
    Manuscript Submission Guidelines page of our Author Gateway.

    6.1.1 Title and Authors (On a separate title page)

    • Title should be in upper and lower case (Do not use all UPPERcase)
    • Author first name (or initials), middle initial, and last name (surname, family name)
    • and degree(s)
    • Affiliations: use 1, 2, etc. after the degree
    • Put an * after the name of the corresponding author

    6.1.2 Manuscript preparation

    Please add line and page numbers to your document. 

    Abstract
    The abstract should be 250-300 words and should reflect the results. Describe the
    purpose of the study and briefly explain how the study was performed. Summarize the
    most important observations and their significance. Do not use abbreviations in the
    abstract.

    Keywords
    Following the abstract, please list 5-6 keywords for indexing the article. Keywords, along
    with the abstract and title, are central to ensuring that readers can search for and find
    your article online. For this reason, to aid in search-ability, words in the title should not
    be used as keywords. For keyword suggestions, please visit the National Library of
    Medicine’s Medical Subject Headings (MeSH®) website
    .

    Abbreviations
    Please include a list of all abbreviations used in the manuscript. These should be listed
    in alphabetical order. (Example: MRI, Magnetic Resonance Imaging; RT, Radiation
    Therapy)

    Introduction
    Provide background that allows readers outside the discipline to understand the significance
    of the study. Include a brief review of important literature in the relevant field.

    Materials and Methods
    Please do not use numbering or subheadings. Describe in detail any new methods or
    protocols used, in order that other investigators can replicate the study. Older, better known
    methods may be cited in references but should be described enough that the
    reader may understand the method. Manufacturer names of reagents and equipment used should be included.

    For immunohistochemistry, blots, and gels the following should be included: catalog numbers, manufacturer names, and dilutions of antibodies. While the journal does not require use of RRIDs, it is recommended. Raw data for immunohistochemistry, blots, gels, cell assays are recommended to be included at submission and can be uploaded as the Research Data file type.

    Specific Reporting Guidelines
    Medical research involving human subjects must be conducted according to the World
    Medical Association Declaration of Helsinki. Submitted manuscripts should conform to
    the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of
    Scholarly Work in Medical Journals, and all papers reporting animal and/or human
    studies must state in the methods section that the relevant Ethics Committee or
    Institutional Review Board provided (or waived) approval. Please ensure that you have
    provided the full name and institution of the review committee, the approval number, and date of approval. For research articles, authors are also required to state in the
    methods section whether participants provided informed consent and whether the
    consent was written or verbal.

    Human Subject Research
    If using human subjects, the title page must include ethics statements that
    specify:

    • The name of the approving institutional review board (IRB) or equivalent
      committees, the approval number, and the date of approval. A copy of the ethics form should be included as a supplmental file with the submission. If approval was not obtained, a detailed statement explaining the reason is required. A version of the statement blinded for peer review should be included in the materials and methods section.
    • Nature of Informed consent – oral or written. If oral, how the consent
      was documented should be stated in the manuscript. If written consent
      was not obtained, the reasons should be stated in the materials and methods section of the manuscript.

    Animal Research
    The methods section of the manuscript reporting animal research must include
    ethics statements that specify the relevant ethics committee approving the
    research, the approval number, and date of approval. A copy of the ethics form should be included as a supplmental file with the submission. If ethical approval was not required,
    reasons should be stated in the manuscript. Relevant details to minimize
    suffering of the animal should be mentioned.

    Cell Line Research
    The methods section should state the origin of the cell lines. In cases of established
    cell lines, in addition to origin, the commercial source should be given. If
    previously unpublished new cell lines were used, the source should be
    disclosed.

    For prospective studies, the type of study needs to be indicated in the abstract and materials and methods section. Studies must be reported according to the relevant Equator network guideline. The materials and methods section should include a statement that the study has followed the relevant guideline and the guideline should be cited. The completed relevant reporting checklist must be included as a supplemental file at submission. For randomised trials, the CONSORT statement must be followed. Clinical trials must be registered with a publicly accessible database prior to submission. The registration number must be included at the end of the abstract and in the materials and methods section.

    For retrospective studies, the type of study needs to be indicated in the abstract and materials and methods section. Studies must be reported according to the relevant Equator network guideline. The materials and methods section should include a statement that the study has followed the relevant guideline and the guideline should be cited. The completed relevant reporting checklist must be included as a supplemental file at submission.

    For systematic reviews and meta-analyses, the study type needs to be indicated in the title, abstract, and materials and methods. Studies must be reported according to the relevant Equator network guideline. The PRISMA flow diagram should be included as a figure. The study should be registered with PROSPERO and the registration should be included in the submission.

    Results
    Explain how the results relate to the premise of the study especially in relation to
    previous related studies and how the present study results might have potential in
    directing future research.

    Discussion
    Describe the interpretation of the data.

    Conclusion (Optional)
    Avoid overemphasizing the conclusion.

    Conflict of Interests Statement
    At the end of the manuscript, before the Acknowledgements section, statements
    related to conflicts of interest must appear.

    Acknowledgments
    List the names of the individuals along with the contributors who have participated in
    some capacity but cannot be qualified as authors.

    Funding
    Disclose if any funds were received to conduct the research.

    References
    Technology in Cancer Research & Treatment adheres to AMA reference style. In the
    references section (i.e., bibliography), please list references in the same order as they
    were cited in the manuscript. When a website is cited as a reference, provide the date
    that the website was last accessed.

    Unpublished data and personal correspondence may be cited as references within the
    text itself and are not to be included in the list of references. Authors are fully
    responsible for the accuracy of references used, and all text quoted. Manuscripts
    submitted in any other format may delay the publication of your article.

    6.2 Artwork, figures and other graphics

    All figures and illustrations should contain clean and clear graphics, and must be submitted
    electronically in their original format (e.g., png, jpeg, tif).

    Line art must have a resolution of at least 900 dpi (dots per inch). Electronic photographs,
    radiographs, CT scans, MRIs, all medical imaging, and all scanned images must have a resolution
    of at least 300 dpi. If fonts are used in the artwork, they must be embedded in the files. Color
    images must be created/scanned and saved and submitted as CMYK files. Please note that
    artwork downloaded from the internet (JPEG or GIF files) cannot be used.

    Ensure that fonts are clear and easy to read should the figures be resized to a 1-column or 2-
    column format during the layout process of publication. Please use the following guidelines
    when preparing your image files:

    Example of Figure

    For graphics reprinted from another source, provide written permission for reproduction from
    the copyright owner. Include full credit in the manuscript’s text, figure legends, and/or in the
    acknowledgment section, as appropriate.

    Embed all images in the manuscript and submit separate files for each image in the original
    format it was created (e.g., png, jpeg, tiff).

    For guidance on the preparation of illustrations, pictures and graphs in electronic format, please
    visit Sage’s Manuscript Submission Guidelines

    Figures supplied in color will appear in color online.

    Equations
    If your manuscript is in .docx format and contains equations, make sure the equations are
    editable. Equations must be placed in brackets [ ].

    Tables
    Tables should have a concise title and should not occupy more than one printed page. Indicate
    in red where to place the Figures and Tables. Create tables in Word format within the
    manuscript.

    Use Arabic numerals to name tables (e.g. Table 1). Cite tables in the text in consecutive order.
    For each table, provide a table heading that clearly and concisely explains the content of the
    table. Indicate table footnotes with lower-case letters in superscript font. Place the information
    for the footnote beneath the body of the table.

    If a table will be submitted as a separate document, the filename should contain the surname of
    the first author and match its label in the manuscript (e.g., SMITH Table 1).

    6.3 Supplemental material

    This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.)
    alongside the full-text of the article. For more information please refer to our guidelines on submitting
    supplemental files

    6.4 Reference style.

    Technology in Cancer Research & Treatment adheres to the AMA reference style. Please review
    the guidelines on AMA to ensure your manuscript conforms to this reference style.

    If you use EndNote to manage references, you can download the AMA output file here.

    6.5 English language editing services

    Authors seeking assistance with English language editing, translation, or figure and manuscript
    formatting to fit the journal’s specifications should consider using Sage Language Services. Visit
    Sage Language Services on our Journal Author Gateway for further information. 

    Back to top

    7. Submitting your manuscript

    7.1 How to submit your manuscript 

    Technology in Cancer Research & Treatment is hosted on Sage Track, a web-based online
    submission and peer review system powered by ScholarOne™ Manuscripts. Visit
    https://mc.manuscriptcentral.com/TCRT to login and submit your article online. 

    IMPORTANT: Please check whether you already have an account in the system before trying to
    create a new one. If you have reviewed or authored for the journal in the past year it is likely
    that you will have had an account created. For further guidance on submitting your manuscript
    online please visit ScholarOne Online Help.

    7.2 Title, keywords and abstracts

    Please supply a title, short title, an abstract and keywords to accompany your article. The title,
    keywords and abstract are key to ensuring readers find your article online through online search
    engines such as Google. Please refer to the information and guidance on how best to title your
    article, write your abstract and select your keywords by visiting the Sage Journal Author
    Gateway for guidelines on How to Help Readers Find Your Article Online

    7.3 Information required for completing your submission

    Provide full contact details for the corresponding author including email, mailing address and
    telephone numbers. Academic affiliations are required for all co-authors. These details should
    be presented separately to the main text of the article to facilitate anonymous peer review.

    You will be asked to provide contact details and academic affiliations for all co-authors via the
    submission system and identify who is to be the corresponding author. These details must
    match what appears on your manuscript. At this stage please ensure you have included all the
    required statements and declarations and uploaded any additional supplementary files
    (including reporting guidelines where relevant).

    7.4 ORCID

    As part of our commitment to ensuring an ethical, transparent and fair peer review process Sage is a
    supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique
    and persistent digital identifier that distinguishes researchers from every other researcher, even
    those who share the same name, and, through integration in key research workflows such as
    manuscript and grant submission, supports automated linkages between researchers and their
    professional activities, ensuring that their work is recognized.

    The collection of ORCID iDs from corresponding authors is now part of the submission process of this
    journal. If you already have an ORCID iD you will be asked to associate that to your submission
    during the online submission process. We also strongly encourage all co-authors to link their ORCID
    ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when
    prompted, sign in to your ORCID account and our systems are automatically updated. Your ORCID iD
    will become part of your accepted publication’s metadata, making your work attributable to you and
    only you. Your ORCID iD is published with your article so that fellow researchers reading your work
    can link to your ORCID profile and from there link to your other publications.

    If you do not already have an ORCID iD please follow this link to create one or visit our ORCID
    homepage
    to learn more.

    7.5 Information required for completing your submission

    You will be asked to provide contact details and academic affiliations for all co-authors via the submission
    system and identify who is to be the corresponding author. These details must match what appears on
    your manuscript. The affiliation listed on the manuscript should be the institution where the research was
    conducted. If an author has moved to a new institution since completing the research, the new affiliation
    can be included in a manuscript note at the end of the paper. At this stage please ensure you have
    included all the required statements and declarations and uploaded any additional supplementary files
    (including reporting guidelines where relevant).

    7.6 Permissions

    Authors are responsible for obtaining permission from copyright holders for reproducing any
    illustrations, tables, figures or lengthy quotations previously published elsewhere. For further
    information including guidance on fair dealing for criticism and review, please visit our
    Frequently Asked Questions on the Sage Journal Author Gateway.

    Back to top

    8. On acceptance and publication

    If your paper is accepted for publication after peer review, you will first be asked to complete the
    contributor’s publishing agreement. Once your manuscript files have been checked for Sage Production,
    the corresponding author will be asked to pay the article processing charge (APC) via a payment link.
    Once the APC has been processed, your article will be prepared for publication and can appear online
    within an average of 30 days. Please note that no production work will occur on your paper until the
    APC has been received.

    8.1 Sage Production

    Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will  be made available to the corresponding author via our editing portal Sage Edit, or by email to the corresponding author and should be returned promptly.  Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. 

    8.2 Online publication

    One of the many benefits of publishing your research in an open access journal is the speed to
    publication. With no page count constraints, your article will be published online in a fully
    citable form with a DOI number as soon as it has completed the production process. At this time
    it will be completely free to view and download for all. 

    8.3 Promoting Your Article

    Publication is not the end of the process! You can help disseminate your paper and ensure it is
    as widely read and cited as possible. The Sage Author Gateway has numerous resources to help
    you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.

     

    Back to top

    9. Further information

    Any correspondence, queries or additional requests for information on the Manuscript Submission
    process should be sent to the Technology in Cancer Research & Treatment Editorial Office | tct@sagepub.com 

    Back to top